These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 34934970)

  • 21. Metformin use and hospital attendance-related resources utilization among diabetic patients with prostate cancer on androgen deprivation therapy: A population-based cohort study.
    Lee YHA; Hui JMH; Chung CT; Liu K; Dee EC; Ng K; Tse G; Chan JSK; Ng CF
    Cancer Med; 2023 Apr; 12(8):9128-9132. PubMed ID: 36734312
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detectable prostate-specific antigen Nadir during androgen-deprivation therapy predicts adverse prostate cancer-specific outcomes: results from the SEARCH database.
    Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
    Eur Urol; 2014 Mar; 65(3):620-7. PubMed ID: 23245686
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antihypertensive drug use and prostate cancer-specific mortality in Finnish men.
    Siltari A; Murtola TJ; Talala K; Taari K; Tammela TLJ; Auvinen A
    PLoS One; 2020; 15(6):e0234269. PubMed ID: 32598349
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quality of Life after Radical Prostatectomy or Watchful Waiting With or Without Androgen Deprivation Therapy: The SPCG-4 Randomized Trial.
    Johansson E; Steineck G; Holmberg L; Johansson JE; Nyberg T; Bill-Axelson A;
    Eur Urol Oncol; 2018 Jun; 1(2):134-142. PubMed ID: 31100237
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies.
    Touijer KA; Karnes RJ; Passoni N; Sjoberg DD; Assel M; Fossati N; Gandaglia G; Eastham JA; Scardino PT; Vickers A; Cozzarini C; Montorsi F; Briganti A
    Eur Urol; 2018 Jun; 73(6):890-896. PubMed ID: 29042125
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer.
    Crawley D; Garmo H; Rudman S; Stattin P; Häggström C; Zethelius B; Holmberg L; Adolfsson J; Van Hemelrijck M
    Int J Cancer; 2016 Dec; 139(12):2698-2704. PubMed ID: 27557616
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial.
    Johnston TJ; Shaw GL; Lamb AD; Parashar D; Greenberg D; Xiong T; Edwards AL; Gnanapragasam V; Holding P; Herbert P; Davis M; Mizielinsk E; Lane JA; Oxley J; Robinson M; Mason M; Staffurth J; Bollina P; Catto J; Doble A; Doherty A; Gillatt D; Kockelbergh R; Kynaston H; Prescott S; Paul A; Powell P; Rosario D; Rowe E; Donovan JL; Hamdy FC; Neal DE;
    Eur Urol; 2017 Mar; 71(3):381-388. PubMed ID: 27720537
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metformin may offer no protective effect in men undergoing external beam radiation therapy for prostate cancer.
    Ranasinghe WKB; Williams S; Ischia J; Wetherell D; Baldwin G; Shulkes A; Sengupta S; Bolton D; Patel O
    BJU Int; 2019 May; 123 Suppl 5():36-42. PubMed ID: 31012989
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary Gleason grade 4 at the positive margin is associated with metastasis and death among patients with Gleason 7 prostate cancer undergoing radical prostatectomy.
    Viers BR; Sukov WR; Gettman MT; Rangel LJ; Bergstralh EJ; Frank I; Tollefson MK; Thompson RH; Boorjian SA; Karnes RJ
    Eur Urol; 2014 Dec; 66(6):1116-24. PubMed ID: 25052213
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients.
    He XX; Tu SM; Lee MH; Yeung SJ
    Ann Oncol; 2011 Dec; 22(12):2640-2645. PubMed ID: 21415239
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.
    Van Den Eeden SK; Lu R; Zhang N; Quesenberry CP; Shan J; Han JS; Tsiatis AC; Leimpeter AD; Lawrence HJ; Febbo PG; Presti JC
    Eur Urol; 2018 Jan; 73(1):129-138. PubMed ID: 28988753
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of Concomitant Medications on Biochemical Outcome in Localised Prostate Cancer Treated with Radiotherapy and Androgen Deprivation Therapy.
    Roy S; Malone S; Grimes S; Morgan SC
    Clin Oncol (R Coll Radiol); 2021 Mar; 33(3):181-190. PubMed ID: 32994091
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metformin Use is Associated with Improved Survival for Patients with Advanced Prostate Cancer on Androgen Deprivation Therapy.
    Richards KA; Liou JI; Cryns VL; Downs TM; Abel EJ; Jarrard DF
    J Urol; 2018 Dec; 200(6):1256-1263. PubMed ID: 29940252
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy.
    Touijer KA; Mazzola CR; Sjoberg DD; Scardino PT; Eastham JA
    Eur Urol; 2014 Jan; 65(1):20-5. PubMed ID: 23619390
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
    Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
    J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association between Androgen Deprivation Therapy and the Risk of Inflammatory Rheumatic Diseases in Men with Prostate Cancer: Nationwide Cohort Study in Lithuania.
    Drevinskaite M; Dadoniene J; Miltiniene D; Patasius A; Smailyte G
    J Clin Med; 2022 Apr; 11(7):. PubMed ID: 35407647
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.
    Brockman JA; Alanee S; Vickers AJ; Scardino PT; Wood DP; Kibel AS; Lin DW; Bianco FJ; Rabah DM; Klein EA; Ciezki JP; Gao T; Kattan MW; Stephenson AJ
    Eur Urol; 2015 Jun; 67(6):1160-1167. PubMed ID: 25301759
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes.
    Preisser F; Chun FKH; Pompe RS; Heinze A; Salomon G; Graefen M; Huland H; Tilki D
    Eur Urol; 2019 Jul; 76(1):106-114. PubMed ID: 30772034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.